Background. We aimed to determine the consequences of delayed human immunodeficiency virus type 1 (HIV-1) infection diagnosis by comparing long-term outcomes depending on the time of combination antiretroviral therapy (cART) initiation in patients diagnosed during primary HIV infection (PHI).
International guidelines now recommend universal treatment of human immunodeficiency virus type 1 (HIV-1) infection, initiated as soon as possible [1] . Combination antiretroviral therapy (cART) initiation during primary HIV infection (PHI) reduces infectivity [2] and limits CD4 + T-lymphocyte depletion and viral reservoir size, both predictors of progression [3] [4] [5] [6] . Whether it could reduce, or even normalize, systemic inflammation, microbial translocation, and monocyte activation, which are associated with the occurrence of comorbidities in HIV infection [7] , is still debated. It may depend on the earliness of ART initiation, the degree of pre-ART immunodeficiency deficit, and the duration of treatment [8] . Besides, only 39% of HIV infections diagnosed in France in 2013 were early (CD4 + T-cell count ≥500 cells/μL or during PHI) [9] . Studies comparing effect of continuous ART initiated during PHI vs chronic infection are therefore of interest, as they reflect the consequences of delayed HIV infection diagnosis. However, few data are available [3, [10] [11] [12] [13] , especially those on markers of inflammation and activation over a long-term follow-up (>4 years). Since 1996, the French National Agency for Research on AIDS and Viral Hepatitis (ARNS) Primary Infection Cohort (PRIMO) has enrolled French patients diagnosed during PHI. We thus could compare the long-term impact of cART initiation in PHI vs chronic infection on immunovirological and inflammatory outcomes, in patients followed since PHI diagnosis.
an incomplete Western blot (ie, absence of anti-p68 and/or anti-p34); (2) detectable p24 antigenemia or detectable plasma viral load (VL), associated with either a negative or weakly reactive enzyme-linked immunosorbent assay (ELISA), or a negative Western blot; or (3) an interval <3 months between a negative and positive ELISA. The date of infection was estimated as described before [14] . CD4 + and CD8 + T-cell counts and plasma VL were measured at months 1, 3, and 6 and every 6 months thereafter. Samples of whole blood and plasma were collected and frozen at inclusion, at months 1, 3, 6, 12, and every 12 months thereafter. Patients were treatment naive at enrollment. The decision to initiate cART was left to the physicians. Before 2002, no specific guidelines were available for PHI. Between 2002 and 2010, ART initiation was based on the presence of symptoms or CD4 + T-cell counts, with an increasing cutoff of 200-500 cells/μL in 2010. Since 2013, cART initiation has been recommended for all PHI diagnoses, regardless of CD4 + T-cell count [15] . The cohort was approved by the Ile-deFrance-3 Ethics Committee and patients gave their informed consent to participate.
Study Participants
We selected patients based on the following criteria (1) treated for ≥36 months, without an interruption >15 days, from PHI (cART initiation within the month following PHI diagnosis; immediate ART) or the chronic infection (>12 months after estimated date of infection; deferred ART); (2) with a sustained virological response (ie, VL <50 copies/mL within 9 months following cART initiation and then >90% of VL measurements <50 copies/mL during the first 36 months); (3) with available frozen samples from cART initiation. In 2014, an additional fresh blood sampling was proposed to patients on cART still being controlled (last follow-up visit on cART). We also used samples from 40 healthy blood donors (Établissement Français du Sang, Paris, France), for comparison (median age, 37.5 years; male sex, 53%) [16] . . They were measured in a central laboratory from samples frozen at 4 time-points: enrollment (PHI), within 6 months prior to cART initiation for the patients in the deferred group (pre-ART), after 36 ± 6 months on cART (M36), and at the last visit on cART. IL-1α, IP-10, TNF-α, LAP, IL-10, and MCP-1 were measured by FlowCytomix multiplex immunoassay (eBioscience Inc), and IL-6, sCD14, and sCD163 by specific ELISA assays (Human IL-6 Platinum ELISA, eBioscience; Human CD14 DuoSet ELISA and Human CD163 DuoSet ELISA, R&D Systems). Samples with undetectable levels were attributed half the threshold value.
Flow cytometry immunophenotyping was performed at the last visit on whole blood samples. We measured the expression of CD57, HLA-DR, and CD38 on CD4 + and CD8 + T cells (BD Biosciences). Ultrasensitive VL (usVL) was measured at a central laboratory on last visit samples using an ultrasensitive real-time polymerase chain reaction (PCR) technique (GENERIC HIV, Biocentric), with a 1-8 copies/mL threshold, depending on available plasma volumes. Total cell-associated HIV-1-DNA was measured at a central laboratory from whole blood samples, frozen at enrollment and during follow-up, using the realtime PCR GENERIC HIV-DNA assay [17] , with a threshold of <60 copies/10 6 peripheral blood mononuclear cells (PBMCs).
Statistical Analysis
We modeled and compared the dynamics of CD4 + T-cell counts, CD4:CD8 ratios, and HIV DNA levels for the immediate vs deferred ART group using piecewise linear mixed-effects models, with random coefficients. Changes of slope were chosen by minimization of Akaike information criterion. Available measurements were analysed until 80 months, the median duration on cART in the deferred ART group. We compared inflammatory marker levels of immediate ART and deferred ART patients at 4 time-points: PHI, pre-ART, M36, and last visit on cART. We used the Kruskal-Wallis test for continuous data, and the χ 2 or Fisher exact tests for categorical data. At the last visit, usVL, inflammatory marker levels and T-cell marker expression were compared between groups, and with the noninfected group. We used tobit models for left-censoring data to account for differences between immediate and deferred ART groups for treatment duration at the last visit.
Comparisons across time-points within groups were performed with the Wilcoxon signed-rank test. Correlations were determined with the Spearman rank coefficient. Statistical tests were considered to be significant if P < .05. Analyses were performed using Stata version 14 software (Stata Corp 2014) and R (R Core Team 2015) software products.
RESULTS

Patient Characteristics
We studied 150 patients enrolled in the PRIMO cohort between 1997 and 2009: 77 and 73 in the immediate and deferred groups, respectively. They were mostly white men (79%), of median age 37 years at PHI diagnosis (Table 1) . At PHI diagnosis, patients in the immediate ART group were more often symptomatic, and had lower CD4 + T-cell counts and CD4:CD8 ratios than deferred ART patients (95% vs 80% symptomatic PHI, P = .01; 414 vs 539 cells/μL and 0.4 vs 0.6, both P = .0001) and higher VL and HIV DNA levels (5.5 vs 4.6 log 10 copies/mL, P < .0001; 3.5 vs 3.2 log 10 copies/10 6 PBMCs, P = .001, respectively). cART was initiated in the immediate ART group within a median time of 43 days (range, 20-123) after estimated date of infection vs 29 months in the deferred ART group (median CD4 + T-cell count, 317 cells/μL; median VL, 4.6 log 10 copies/mL; median HIV DNA level, 3.5 log 10 copies/10 6 PBMCs). The median duration of cART was 91.0 and 73.5 months for the immediate and deferred ART groups, respectively.
Modeling of Immunovirological Marker Dynamics on cART
The CD4 + T-cell count and the CD4:CD8 ratio decreased before cART in deferred ART patients. They had lower mean CD4 + T-cell count but similar CD4:CD8 ratio than immediate group at ART initiation ( Table 2 ). Patients treated from PHI showed faster CD4 + T-cell count and CD4:CD8 ratio increases and reached higher CD4 + T-cell count and CD4:CD8 ratio during the first months of ART ( Figure 1A and 1B; Supplementary Table 1) . However, the deferred group eventually reached similar CD4 + T-cell count and CD4:CD8 ratio than the immediate group, after more than 43 and 48 months, respectively, of ART. Immediate ART patients had higher HIV DNA levels at cART initiation than deferred ART patients (estimated mean, 3.4 vs 3.2 log 10 copies/10 6 PBMCs, P = .02; Table 2 ). They experienced a greater decrease of HIV DNA levels over the first 27 months, leading to a mean difference of -0.6 log 10 copies/10 6 PBMCs at 27 months (P < .0001) that was significantly sustained, until the last modeling time-point on cART-that is, 80 months ( Figure 1C ; Supplementary Table 1 ).
The effect of immediate vs deferred ART initiation on the CD4 + T-cell count, the CD4:CD8 ratio, and HIV DNA levels remained statistically significant after adjustment for year of infection, CD4 + T-cell count, and VL at PHI. 
Inflammatory Marker Levels
At PHI diagnosis, IP-10, sCD14, and TNF-α levels were significantly higher in patients in Fiebig stages II-III than in later stages, whereas sCD163 levels were lower (Supplementary Figure 1) . At PHI, immediate ART patients had, or tended to have, higher levels of MCP-1 (P = .01), IP-10 (P = .001), sCD14 (P < .0001), TNF-α (P = .08), and sCD163 (P = .09) than deferred ART patients. The other markers levels of the other markers were similar between groups (Supplementary Figure 2) . The levels of MCP-1 (P = .03), sCD14, and sCD163 (both P < .0001) increased spontaneously after PHI during the initial untreated period for the deferred ART group, whereas IL-6 levels decreased (P = .02). We observed no significant changes for the other markers. Overall, only the levels of IP-10 (P = .001) and TNF-α (P = .01) were still higher in immediate ART patients at cART initiation.
After 36 months of cART, IP-10, sCD163, and MCP-1 levels had significantly decreased and I-FABP levels increased in both groups (Supplementary Figure 2) . IL-6 levels decreased in the immediate ART group, whereas they remained stable in the deferred ART group after its initial spontaneous decrease. We observed no statistically significant changes for sCD14, LAP, or IL-10 levels, leading to similar levels in the 2 groups at month 36. TNF-α levels did not decrease under cART and thus immediate ART patients still exhibited higher TNF-α levels (P = .05). IL-1α levels decreased in patients with a detectable pre-ART level in both groups. Deferred ART patients achieved lower IL1-α levels than immediate ART patients (P = .02). At the last visit on cART, inflammation marker levels were similar between groups, even after adjusting for treatment duration.
Last Follow-up Visit on cART
At the last visit in 2014, 106 patients were still on active follow-up and virologically controlled, after a median of 82 months on cART, and agreed to undergo a supplementary sample (Table 3) . Median age was 48 years, median body mass index (BMI) 23.5 kg/m 2 and 40% of patients were smokers.
Four patients had been treated for hepatitis C virus (HCV) infection during follow-up and achieved an undetectable HCV viral load at the last visit. No cases of hepatitis B virus infection were reported. Median CD4 + T-cell count was 683 cells/μL, 12% of patients still had a CD4 + T-cell count <500 cells/μL and 45% had a CD4:CD8 ratio <1. The current cART regimen was mostly (65%) nonnucleoside reverse transcriptase inhibitor (NNRTI) based. The immediate and deferred ART groups were similar for sex, origin, age, smoking, coinfection, BMI, and ongoing cART regimen. They had similar usVL: 67% of patients from the immediate ART group and 64% from the deferred ART group had undetectable usVL. Among patients with a detectable usVL, the median levels were 4.5 (range, 1-53) copies/mL and 5 (range, 1-134) copies/mL, respectively. HIV DNA levels were <2 log 10 copies/10 6 PBMCs for 40 and 7% of patients of immediate and deferred ART groups, respectively (P = .002). Plasma inflammatory marker levels were similar between immediate and deferred ART groups. HIV-infected patients still had higher levels of sCD14, MCP-1, IP-10, TNF-α, and IL-10 than noninfected subjects (Figure 2 T-cell activation levels in both the immediate and deferred ART groups were higher than in HIV-negative subjects (P = .02 and P = .01, respectively).
Factors Associated With Long-term Inflammatory and Immunovirological Marker Levels
At the last visit on cART, HIV DNA levels were higher in patients with detectable than those with undetectable usVL (2.7 vs 2.4 log 10 copies/10 6 PBMCs, P = .01). HIV DNA levels did not correlate with CD4 + T-cell counts or CD4:CD8 ratios. None of the inflammatory marker levels correlated with the duration of treatment, CD4 or CD8 T-cell counts, the CD4:CD8 ratio, or HIV DNA levels or usVL. They also did not differ depending on the first-line or current regimen (NNRTI-vs PI-containing). Women had lower HIV DNA and usVL than men (1.9 vs 2.5 log 10 copies/10 6 PBMCs, P = .01; 88% vs 61% undetectable usVL, P = .03) and higher sCD14 levels (P = .003; Supplementary Figure 3 ). Age correlated with MCP-1 levels (r = -0.20, P = .03). Current smokers had, or tended to have, higher MCP-1 (P = .04), IL-10, and usVL (both P = .06). These associations were not observed before cART initiation. BMI correlated with sCD14 level (r = -0.20, P = .03) from PHI until the last visit on cART.
Sensitivity Analyses
We performed sensitivity analyses to ensure that our results were not driven by changes in guidelines and antiretroviral drugs. First, we excluded patients who received a first-line regimen containing unboosted PI, Second, we restricted the analysis to patients treated after 2005, the year of availability for most of the current molecules. Third, we restricted the analysis to symptomatic patients. They all led to results consistent with the main analysis.
DISCUSSION
In a unique cohort of patients followed from PHI diagnosis, we observed that those treated from PHI did not reach lower longterm levels of inflammation/activation markers or usVL than patients treated during chronic infection, despite a longer time spent with higher CD4 + T-cell counts and CD4:CD8 ratios and lower HIV DNA levels while on cART. After a median of 7 years on ART, persisting elevated levels of inflammation and CD8 + T-cell activation were not explained by CD4 + T-cell count, CD4:CD8 ratio, or HIV DNA levels and usVL. Our results confirm the benefit of immediate cART initiation during PHI to enhance the recovery of CD4 + T-cell counts [5, 6, 18] and CD4:CD8 ratio [13, 19] . However, with an extended treatment period, we observed that the deferred group eventually reached a similar level of immune recovery, despite lower CD4 + T-cell counts at ART initiation.
Patients treated in PHI achieved lower long-term HIV DNA levels than those treated during chronic infection [10, 12, 18] , despite a wider initial pool of latently infected cells. Modeling of HIV DNA decay on ART showed a greater decay the first months of ART, both in patients treated since PHI and from chronic infection [20] . ART initiation in PHI accelerates the initial rate of decay, leading to lower levels in the long term [3, 21] . Our patients treated in PHI achieved HIV DNA levels close to those of elite and posttreatment controllers [22, 23] . This result is important as, among patients treated during PHI who interrupted ART, a low HIV DNA level also predicted a longer time to treatment resumption [24, 25] . Because early ART limits HIV reservoir size and preserves central memory CD4 cells, patients treated from PHI with low HIV DNA levels might be good candidates for future HIV cure strategies [26] .
After several years of suppressive ART, 45% of patients had an inverted ratio indicating a persistent immune dysfunction. In a previous study, 96 weeks of ART failed to normalize all CD4:CD8 ratios, though initiated in PHI and even in Fiebig I in some cases [27] . Nevertheless, ART initiated in the days following infection was found to normalize soluble IL-6R, TNF, and D-dimer levels, and to reduce sCD14, C-reactive protein, and hyaluronic acid levels, compared with ART initiation in chronic infection [11] . A very early ART initiation, that is, within days to weeks following infection, could explain these results, as it prevents gut damage, a cause of immune activation [28, 29] . With a median time of 1.5 months at ART initiation elapsed since infection, our study represents, however, a setting closer to standard of care of screening and treatment.
Long-term levels of inflammatory plasma markers were not associated with CD4 + T-cell count, CD4:CD8 ratio, or HIV DNA and usVL levels. This lack of association suggests that (1) HIV-1 persistence may not be driving inflammation/activation after long-term suppressive cART and (2) chronic inflammation may, rather, be driven by non-HIV-related factors, such as age, smoking, BMI, or coinfections [30, 31] . In the Gandhi et al study, the strongest associations for markers of HIV-1 persistence on ART were their pre-ART levels [32] . Interestingly, women had lower HIV DNA and usVL than men at their last visit on cART, in contrast to higher sCD14 levels, whereas there was no sex difference prior to ART. Such sex-specific differences in response to treatment were reported in chronically infected patients [32, 33] , but their immunological basis needs further investigation [34] . Sereti et al previously reported that many markers of monocyte activation failed to normalize even after 2 years of ART initiated early during PHI [11] . We found that a longer time of cART initiated during chronic infection or even PHI failed to fully normalize inflammation or CD8 + T-cell activation.
This suggests that these well-controlled patients are still at risk of non-AIDS events [35, 36] . Nevertheless, when comparing with uninfected subjects [37, 38] , control groups are often not matched to HIV patients for factors that may contribute to systemic inflammation/activation, in particular smoking and HCV coinfection. Normalization of inflammation is therefore difficult to ascertain. Further studies would require better characterization of inflammation in non-HIV-infected patients to ascertain the optimal values for patients on suppressive cART. Our study has some limitations. First, most of the immunovirological markers we measured at the periphery may not reflect processes in the lymphoid tissues. Second, patients with symptomatic PHI or low CD4 + T-cell counts were more likely to start cART in PHI. However, this selection effect is likely to be conservative: Despite lower CD4 + T-cell counts, and higher VL, HIV DNA, and sCD14 levels in PHI, all predictive of progression, patients treated in PHI achieved lower HIV DNA levels but similar levels of inflammation/activation than deferred patients [14, 24, 39] .
In conclusion, the impact of immediate cART on the viral reservoir persisted for at least 7 years of cART, whereas CD4 + T-cell counts, CD4:CD8 ratios, and residual viral replication reached similar levels, irrespective of the timing of cART initiation in patients followed since PHI. Half of the patients in the deferred group initiated cART with a CD4 + T-cell count <300 cells/μL, which is in accordance with the status of patients currently diagnosed in high-and middle-income countries [9] . Thus, our results provide information on long-term consequences of delayed HIV diagnosis and new insights on long-term outcomes of patients treated since PHI. They confirm the benefits of early HIV diagnosis and cART initiation from PHI, but also emphasize the need for complementary strategies to improve long-term outcomes.
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